Vanguard Personalized Indexing Management
DNLI icon

Vanguard Personalized Indexing Management’s Denali Therapeutics DNLI Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Buy
11,953
+331
+3% +$6.8K ﹤0.01% 1690
2026
Q1 		$223K Sell
11,622
-114
-1% -$2.27K ﹤0.01% 1759
2025
Q4 		$194K Sell
11,736
-790
-6% -$13.3K ﹤0.01% 1728
2025
Q3 		$182K Sell
12,526
-2,803
-18% -$40.3K ﹤0.01% 1727
2025
Q2 		$214K Buy
+15,329
New +$216K ﹤0.01% 1595
2025
Q1 		– Sell
-11,377
Closed -$232K – 1863
2024
Q4 		$232K Sell
11,377
-1,513
-12% -$38.7K ﹤0.01% 1458
2024
Q3 		$375K Buy
12,890
+2,100
+19% +$52.1K 0.01% 1242
2024
Q2 		$249K Buy
+10,790
New +$207K ﹤0.01% 1355
2021
Q3 		– Sell
-6,012
Closed -$472K – 1001
2021
Q2 		$472K Buy
+6,012
New +$372K 0.05% 505

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Personalized Indexing Management's DNLI Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Denali Therapeutics (DNLI) stake by 2.8% in Q2 2026, buying an estimated $6.8K and bringing the position to 11,953 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #1690.

Vanguard Personalized Indexing Management first reported a position in DNLI in Q2 2021 and has held it in 9 quarters since. The position peaked at $472K in Q2 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Vanguard Personalized Indexing Management held 11,953 shares of Denali Therapeutics worth $307K as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 331 Denali Therapeutics shares in Q2 2026, an estimated $6.8K.
  • Denali Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1690 holding.
  • Vanguard Personalized Indexing Management first reported a position in Denali Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • Vanguard Personalized Indexing Management's Denali Therapeutics position peaked at $472K in Q2 2021.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.